source
- Healthcare systems lag behind rapid expansion of GLP-1 therapies, raising care and trust challengesGLP-1 drugs have demonstrated that pharmacological treatment can effectively reduce obesity, and regulators have now approved them for additional uses such as cardiovascular risk reduction, metabol…
- Artelo’s oral cannabinoid agonist matches semaglutide weight loss in obese mice, doubles effect when combinedArtelo Biosciences reported that its oral dual cannabinoid agonist, ART27.13, produced weight loss in diet‑induced obese mice that was comparable to the GLP‑1 receptor agonist semaglutide. In a fo…